Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

March 15, 2021

Study Completion Date

September 30, 2023

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

TOL-3021

TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.

OTHER

TOL-3021 Placebo

TOL-3021 Placebo

Trial Locations (23)

10032

Naomi Berrie Diabetes Center, Columbia University, New York

13210

SUNY Upstate Medical University, Syracuse

20782

MedStar Health Research Institute, Hyattsville

21239

MedStar Health Research Institute, Baltimore

22903

University of Virginia, Charlottesville

27517

University of North Carolina Diabetes Care Center, Chapel Hill

28803

Mountain Diabetes and Endocrine Center, Asheville

30322

Emory University, Atlanta

32258

Baptist Health Research Institute, Jacksonville

32610

University of Florida, Gainesville

33136

University of Miami Diabetes Research Institute, Miami

33612

University of South Florida Diabetes Center, Tampa

52242

University of Iowa, Iowa City

64108

Children's Mercy Hospital, Kansas City

78229

Diabetes and Glandular Disease Clinic, P.A., San Antonio

80045

Barbara Davis Center - University of Colorado Denver, Denver

83404

Rocky Mountain Clinical Research, Idaho Falls

92093

Altman Clinical and Translational Research Institute UCSD, San Diego

94143

University of California San Francisco, San Francisco

94305

Stanford University, Stanford

94401

Mills-Peninsula Medical Center, San Mateo

06520

Yale University, New Haven

02215

Joslin Diabetes Center- Adult & Pediatric, Boston

All Listed Sponsors
lead

Tolerion, Inc.

INDUSTRY